ArticleThe Journal of experimental medicine2006
Persistent expression of autoantibodies in SLE patients in remission.
Article in The Journal of experimental medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed.
- Failure of B Cell Tolerance in CVID.Frontiers in immunology · 2019Trial
- Stage-resolved mapping of RP105 (CD180)-negative B cells reveals residual plasmablast-lineage skewing in SLE: a cross-sectional study.Lupus science & medicine · 2026Article
- B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting.Frontiers in immunology · 2026Review
- Autoantibodies in Systemic Lupus Erythematosus: Diagnostic and Pathogenic Insights.Journal of clinical medicine · 2025Review
- B Cell-Derived and Non-B Cell-Derived Free Light Chains: From Generation to Biological and Pathophysiological Roles.International journal of molecular sciences · 2025Review
- Opportunities and limitations of B cell depletion approaches in SLE.Nature reviews. Rheumatology · 2025Review
- Association of hyperactivated transposon expression with exacerbated immune activation in systemic lupus erythematosus.Mobile DNA · 2024Article
- B cell tolerance and autoimmunity: Lessons from repertoires.The Journal of experimental medicine · 2024Review
- Article
- Anti-dsDNA B-Cell ELISpot as a Monitoring and Flare Prediction Tool in SLE Patients.Journal of clinical medicine · 2023Article
- Review
- B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus.Annals of the rheumatic diseases · 2021Article
- Potential role of viral infection and B cells as a linker between innate and adaptive immune response in systemic lupus erythematosus.Immunologic research · 2021Article
- Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD).Clinical and experimental immunology · 2021Review
- New insights into the role of antinuclear antibodies in systemic lupus erythematosus.Nature reviews. Rheumatology · 2020Review
- Evolving story of autoantibodies in systemic lupus erythematosus.Journal of autoimmunity · 2020Review
- Machine Learning to QuantifyFrontiers in immunology · 2020Article
- The Plasma Interleukin (IL)-35 Level and Frequency of Circulating IL-35Scientific reports · 2019Article
- Differences in Self-Recognition between Secreted Antibody and Membrane-Bound B Cell Antigen Receptor.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients.JCI insight · 2018Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A majority of the antibodies expressed by nascent B cells in healthy humans are self-reactive, but most of these antibodies are removed from the repertoire during B cell development. In contrast, untreated systemic lupus erythematosus (SLE) patients fail to remove many of the self-reactive and polyreactive antibodies from the naive repertoire. Here, we report that SLE patients in clinical remission continue to produce elevated numbers of self-reactive and polyreactive antibodies in the mature naive B cell compartment, but the number of B cells expressing these antibodies is lower than in patients with active disease. Our finding that abnormal levels of self-reactive mature naive B cells persist in the majority of patients in clinical remission suggests that early checkpoint abnormalities are an integral feature of SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.